Abbott Laboratories

Abbott Laboratories is a 'dividend king' and a blue chip investment, particularly appealing due to significant insider buying. The recent closure of the DOJ's criminal probe into Abbott's Sturgis plant removes a major legal overhang, providing clearer visibility on remaining liabilities. The company is also launching 8 new nutritional products this year, which investors hope will signal a turnaround in its nutrition segment. Additionally, the acquisition of Exact Sciences enhances Abbott's oncology diagnostics capabilities, further strengthening its robust product line. We are currently underwater by about 7% but have been adding to this position.

Abbott Laboratories is a 'dividend king' and a blue chip investment confirmed by significant insider buying. The recent closure of the DOJ's criminal probe into Abbott's Sturgis plant removes a major legal overhang, providing clearer visibility on remaining liabilities. The company is launching eight new nutritional products this year, aiming for a turnaround in its nutrition segment, while the integration of Exact Sciences is expected to enhance its oncology diagnostics division. We are currently underwater by about 7% but have been adding to this position.

Abbott Laboratories is a US dividend aristocrat that has increased its distributions for 54 years in a row. At the time of purchase, the P/E ratio for the current year was 18, which was well below the historic average of 22 to 24. The business model is based on four pillars, with Medical Devices accounting for approximately 45% of sales revenues. Abbott has a strong competitive advantage in electrophysiology and is expanding its cancer diagnostics with Exact Sciences. Despite temporary challenges, all signs continue to point to growth.

During the quarter, we initiated a position in Abbott Laboratories, a diversified healthcare company with leading franchises across medical devices, diagnostics and nutrition. Recent operational challenges have weighed on the share price, but we believe many of these issues are temporary rather than structural. The company has increased its dividend for more than 50 consecutive years, continues to invest heavily in innovation and, in our view, offers an attractive combination of quality, resilience and valuation.

We started new partial positions in Abbott Laboratories (ABT) because we believe that the company is an attractive investment for the portfolio due to its recurring revenues, strong balance sheet, and 54 years of dividend increases. The stock has pulled back from a 52-week high of $139 to under $90, trading at less than 16 times estimated 2026 earnings, which represents a 25% discount to the market and its own P/E multiple history. At our purchase price, the dividend yield was 2.8%.

We started new partial positions in Abbott Laboratories (ABT) because we believe that the company is an attractive investment for the portfolio due to its recurring revenues, strong balance sheet, and 54 years of dividend increases. The stock has pulled back from a 52-week high of $139 to under $90, trading at less than 16 times estimated 2026 earnings, which is a 25% discount to the market and its own P/E multiple history. At our purchase price, the dividend yield was 2.8%.

Abbott Laboratories continues to be a strong holding in our portfolio, reflecting our confidence in its growth potential and market position. The company has demonstrated resilience and innovation in the health care sector, which is critical for long-term value creation. Our decision to add to this position underscores our belief in Abbott's ability to capitalize on emerging opportunities and maintain its competitive edge.

Abbott Laboratories (ABT) negatively impacted performance as guidance in the nutrition business flagged and growth decelerated elsewhere. The company is facing challenges in its nutrition segment, which has seen a deceleration, indicating potential difficulties in maintaining its competitive position. This has raised concerns about its future growth prospects, leading to a bearish outlook on the stock.

Abbott Laboratories is a key holding in our portfolio, reflecting our confidence in its growth potential and value proposition. The company has demonstrated strong performance metrics, contributing positively to our strategy. We believe that Abbott's robust product pipeline and market position will continue to drive its success in the health care sector, making it an attractive investment opportunity.

Abbott Laboratories is a 'dividend king' so whenever we have an opportunity to buy a blue chip confirmed by insider buying, it’s almost an automatic buy. The purchase of Exact Sciences provides them a Grail-like MCED cancer diagnostic to test their already robust product line. We are underwater by about 7% and will likely add to this position.